Press release
Nutex Health Announces Pricing of $10.0 Million Registered Direct Offering of Common Stock and Warrants
HOUSTON, Jan. 23, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced that it has entered into a
About this update from Nutex Health Inc.
[{"type":"text","content":"HOUSTON, Jan. 23, 2024 /PRNewswire/ -- Nutex Health Inc. (\"Nutex Health\" or the \"Company\") (NASDAQ: NUTX), today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor whereby the investor has agreed to purchase 66,666,666 shares of common stock and warrants to purchase up to an aggregate of 66,666,666 shares of common stock at a purchase price of $0.15 per share and accompanying warrant in a registered direct offering. The warrants have an exercise price of $0.15 per share, are exercisable immediately, and will expire five years following the date of issuance.\n\nMaxim Group LLC is acting as the sole placement agent in connection with the offering.\nThe gross proceeds to Nutex Health are estimated to be $10.0 million before deducting the placement agent fees and other offering expenses. The offering is expected to close on or about January 25, 2024, subject to the satisfaction of customary closing conditions.\nThe offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-270886) previously filed with the U.S. Securities and Exchange Commission (\"SEC\"), which was declared effective on April 7, 2023. The securities may be offered only by means of the prospectus supplement and the accompanying prospectus that form a part of the registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the registered direct offering may be obtained, when available, by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (212) 895-3745 or by email at [email protected]. A final prospectus supplement related to the offering will be filed with the SEC and will be available free of charge by visiting EDGAR on the SEC's website at www.sec.gov.\nThis press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with th...